Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of GV20-0251 in advanced or refractory malignant solid tumors
CTR20252531Phase 2Active
- Sponsor
- SeekIn
- Start
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of GV20-0251 in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), non-small cell lung cancer (NSCLC) and 15 more (11 arms), sponsored by SeekIn. Primary endpoints: Treatment-emergent adverse events in Part A and Objective response rate in Part B. Started Jul 2025; status: active.
02
Drugs
GV20-0251
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)non-small cell lung cancer (NSCLC)intraocular melanomamelanoma
Beyond the preview
Go deeper on CTR20252531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252531.